Genital Diseases, Female  >>  volociximab (M200)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
volociximab (M200) / AbbVie, Biogen
NCT00516841 / 2007-003984-33: A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Terminated
2
16
US, Canada
Volociximab, M200
Facet Biotech, Biogen
Ovarian Cancer, Peritoneal Neoplasms
04/08
04/08
NCT00635193 / 2007-000509-31: Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Completed
1/2
138
US, Europe, RoW
M200 (Volociximab), Liposomal Doxorubicin
AbbVie (prior sponsor, Abbott), Biogen
Ovarian Cancer, Primary Peritoneal Cancer
10/08
10/09

Download Options